Accueil > Actualité
Actualite financiere : Actualite bourse

Sanofi: Europe approves multiple myloma drug

( - Sanofi has announced that the European Commission has approved Sarclisa (isatuximab), in combination with pomalidomide and dexamethasone (pom-dex), for the treatment of adults with relapsed or refractory multiple myeloma (MM).

This approval is for patients who have received at least two previous treatments - particularly lenalidomide and a proteasome inhibitor, and whose disease has progressed during the last treatment.

It is based on the positive results of a randomised phase III clinical trial (ICARIA-MM), where Sarclisa, combined with the pom-dex combination reduced the risk of disease progression or death by 40% compared to the pom-dex combination alone.

Copyright (c) 2020 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.